ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

AUPH Aurinia Pharmaceuticals Inc

4.9001
0.0301 (0.62%)
27 4월(4) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
Aurinia Pharmaceuticals Inc AUPH 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
0.0301 0.62% 4.9001 13:00:07
개장가 저가 고가 종가 전일 종가
4.89 4.86 5.01 4.91 4.87
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
16/04/202423:48BWUPDATE: New Aurinia Presentation Details at the 2024 Bloom..
15/04/202419:00BWAurinia Pharmaceuticals to Release First Quarter Financial..
09/04/202419:00BWAurinia Will Attend 2024 Bloom Burton & Co. Healthcare..
08/03/202406:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/03/202406:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/03/202406:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/03/202406:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/03/202406:10EDGAR2Form 8-K - Current report
29/02/202422:30BWAurinia Receives Exemptive Relief from Canadian Securities..
27/02/202422:30BWAurinia to Participate in Upcoming Investor Healthcare..
23/02/202406:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/02/202406:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/02/202406:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/02/202406:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/02/202406:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/02/202406:19EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
15/02/202420:16EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
15/02/202420:06EDGAR2Form 8-K - Current report
15/02/202420:00BWAurinia Discloses 2023 Year-End Financial and Operational..
15/02/202405:27EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05/02/202422:30BWAurinia Pharmaceuticals to Release 2023 Fourth Quarter and..
05/01/202420:02EDGAR2Form 8-K - Current report
05/01/202420:00BWAurinia Provides Preliminary Unaudited Fourth Quarter and..
20/12/202320:00BWAurinia Submits IND Application to US Food & Drug..
13/11/202320:00BWAurinia Pharmaceuticals Announces Collaboration Partner..
08/11/202300:30BWAurinia Presents Breadth of Data from AURORA Clinical..
03/11/202307:00BWAurinia Presents Breadth of Data at ASN 2023 Demonstrating..
02/11/202319:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202319:01EDGAR2Form 8-K - Current report
02/11/202319:00BWAurinia Pharmaceuticals Reports Third Quarter and Nine..
27/10/202304:00BWAurinia Response in Support of 2023 Updated EULAR..
19/10/202323:31BWCORRECTING and REPLACING Aurinia Pharmaceuticals to Release..
19/10/202319:00BWAurinia Pharmaceuticals to Release Third Quarter Financial..
14/10/202301:00BWAurinia Pharmaceuticals Announces Presentations at American..
23/09/202305:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/09/202305:06EDGAR2Form 8-K - Current report
21/09/202319:00BWAurinia Board of Directors Appoints Dr. Robert T. Foster as..
22/08/202305:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/08/202305:11EDGAR2Form 8-K - Current report
21/08/202319:00BWAurinia Appoints Two New Board Directors with Deep..
03/08/202319:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/08/202319:03EDGAR2Form 8-K - Current report
03/08/202319:00BWAurinia Pharmaceuticals Reports Second Quarter and Six..
20/07/202319:00BWAurinia Pharmaceuticals to Release Second Quarter Financial..
20/07/202301:05BWLong Term Phase 3 Data Published in Arthritis & Rheumatology..
06/07/202321:33EDGAR2Form PX14A6G - Notice of exempt solicitation submitted by..
03/07/202319:06EDGAR2Form 8-K - Current report
30/06/202305:05BWAurinia Board of Directors Announces Exploration of..
20/06/202322:00BWAurinia Showcases Three Oral Presentations for LUPKYNIS®..
01/06/202322:00BWLUPKYNIS® (voclosporin) Achieved Significantly Higher Renal..

최근 히스토리

Delayed Upgrade Clock